Actively Recruiting
Evaluation of Quercetin Supplementation Effects on Cardiometabolic Health Outcomes
Led by University of Central Lancashire · Updated on 2026-09-10
40
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Cardiovascular disease, type 2 diabetes mellitus, and related conditions are major health concerns worldwide, causing significant mortality and health burdens. Researchers are evaluating Quercetin, a dietary supplement, to see if it can improve cardiometabolic outcomes. This study is a randomized, placebo-controlled trial aiming to explore the effects of Quercetin on these health markers, as no prior placebo-controlled research has been conducted. Participants are randomly assigned to receive either 400 mg Quercetin tablets once daily or a placebo tablet daily. The study is double-blinded, meaning neither participants nor researchers know who receives Quercetin or placebo. The intervention lasts 20 days, during which participants take their assigned tablets. Throughout the study, participants will have their systolic and diastolic blood pressure measured at the start and after 20 days. Additional measurements include body fat percentage, waist-to-hip ratio, blood glucose, triglycerides, cholesterol levels, and several assessments related to mood, anxiety, and sleep quality. These measures help assess cardiometabolic health and overall well-being. The total duration of participation is 20 days, with safety and adherence monitored during this period.
CONDITIONS
Brief Title
Effects of Quercetin on Cardiometabolic Outcomes
Research Team
J
Jonathan Sinclair, PhD, DSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here